Prostate cancer (PARPi) [Plasma, cfDNA]
Pilot EQA scheme. Applicable to any lab undertaking molecular testing of BRCA1 and BRCA2 in the context of PARPi prescription, using cfDNA from plasma.
Lung Cancer (NSCLC) [Plasma]
Applicable for all labs undertaking molecular testing of cfDNA in plasma for EGFR and KRAS gene variants in NSCLC.
cfDNA extraction from plasma (Round 1)
Applicable for all labs extracting cfDNA from plasma. Two rounds of EQA per year – purchase each separately.
This EQA will be distributed in MARCH 2025.
cfDNA extraction from plasma (Round 2)
Applicable for all labs extracting cfDNA from plasma. Two rounds of EQA per year – purchase each separately.
This EQA will be distributed in SEPTEMBER 2025.
Breast cancer (ESR1 cfDNA testing) [Plasma]
Applicable to labs undertaking molecular testing of the ESR1 gene in cfDNA
